SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"21575524"
 

Sökning: onr:"21575524" > Prevalence and trea...

Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe EURIKA, a cross-sectional observational study

Halcox, Julian P. (författare)
Banegas, Jose R. (författare)
Roy, Carine (författare)
visa fler...
Dallongeville, Jean (författare)
De Backer, Guy (författare)
Guallar, Eliseo (författare)
Perk, Joep (författare)
Hajage, David (författare)
Henriksson, Karin M. (författare)
Borghi, Claudio (författare)
visa färre...
 (utgivare)
BIOMED CENTRAL LTD 2017
2017
Engelska.
Ingår i: BMC Cardiovascular Disorders. - 1471-2261. ; 17
  • swepub:Mat__t
Abstract Ämnesord
Stäng  
  • Background: Atherogenic dyslipidemia is associated with poor cardiovascular outcomes, yet markers of this condition are often ignored in clinical practice. Here, we address a clear evidence gap by assessing the prevalence and treatment of two markers of atherogenic dyslipidemia: elevated triglyceride levels and low levels of high-density lipoprotein cholesterol. Methods: This cross-sectional observational study assessed the prevalence of two atherogenic dyslipidemia markers, high triglyceride levels and low high-density lipoprotein cholesterol levels, in the study population from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA; N = 7641; of whom 51.6% were female and 95.6% were White/Caucasian). The EURIKA population included European patients, aged at least 50 years with at least one cardiovascular risk factor but no history of cardiovascular disease. Results: Over 20% of patients from the EURIKA population have either triglyceride or high-density lipoprotein cholesterol levels characteristic of atherogenic dyslipidemia. Furthermore, the proportions of patients with one of these markers were higher in subpopulations with type 2 diabetes mellitus or those already calculated to be at high risk of cardiovascular disease. Approximately 55% of the EURIKA population who have markers of atherogenic dyslipidemia are not receiving lipid-lowering therapy. Conclusions: A considerable proportion of patients with at least one major cardiovascular risk factor in the primary cardiovascular disease prevention setting have markers of atherogenic dyslipidemia. The majority of these patients are not receiving optimal treatment, as specified in international guidelines, and thus their risk of developing cardiovascular disease is possibly underestimated.

Ämnesord

Medical and Health Sciences  (hsv)
Medicin och hälsovetenskap  (hsv)

Nyckelord

Atherogenic dyslipidemia
Cardiovascular disease
Epidemiology
Risk factors/global assessment

Hitta via bibliotek

Till lärosätets databas

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy